<DOC>
	<DOCNO>NCT02101957</DOCNO>
	<brief_summary>The purpose study evaluate effect cysteamine patient symptomatic Huntington 's disease compare two group patient ( cysteamine v placebo ) result Unified Huntington 's Disease Rating Scale ( UHDRS , Huntington study group 1996 ) .</brief_summary>
	<brief_title>Multicentric Trial Treatment Huntington 's Disease Cysteamine ( RP103 )</brief_title>
	<detailed_description />
	<mesh_term>Huntington Disease</mesh_term>
	<mesh_term>Cysteamine</mesh_term>
	<criteria>Clinically diseaseregistered least one year , lead consult ( abnormal movement , neuropsychiatric disorder , neuropsychological impairment ) . Unified Huntington 's Disease Rating Scale motor ≥ 5 Total Functional Capacity &gt; 10 ( ≥ 11 ) Huntington Disease diagnose abnormal number CAG repeat : 38 &lt; nucleotide expansion ( CAG ) Age 18 65 Voluntarily Patient Consent Patients willing able take oral medication , comply specific procedure study Severe cognitive impairment neuropsychiatric trouble . No drug compliance previous treatment . Patients contra indication realization image study ( include claustrophobia ) . Patients give write informed consent sign . No national health insurance affiliation Private patient liberty judicial administrative decision , patient supervision . Pregnant woman ( pregnancy test carry systematically woman risk ) lactating . Women could become pregnant study period contraception . Patients develop hypersensitivity cysteamine penicillamine ( indication cysteamine ) . Brain Damage intercurrent MRI . Brain morphological abnormality , characteristic disease . Disease associate neurological repercussion . Affection visceral serious , scalable , involve lifethreatening . Mental disorder may disrupt accession Protocol , include history spontaneous / druginduced hallucination history severe depression require repeated hospitalization , history repeat suicide attempt . Participation progress , interrupt less three month , therapeutic protocol Huntington 's disease . Patients history surgical intervention improve symptom Huntington 's disease graft neuron , deep brain stimulation , infusion neurotrophic agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2013</verification_date>
</DOC>